In this interview, CEO Martin Gouldstone of Oncimmune - a global leader in immune biomarkers and immunodiagnostics – takes Vox Markets through their revised commercial strategy, current health of the sector, size of the addressable market & roadmap & timelines ahead
In this interview Vox speaks to Fintel’s joint CEO Matt Timmins about a busy year on the M&A front as the group continues its mission to build a single unified technology and data platform to help the retail financial services industry deliver improved customer outcomes.
In this interview CEO Sara Barrington of Verici DX - a developer of advanced clinical diagnostics for organ transplant - takes Vox Markets through yesterday's potentially transformational licensing & commercialisation agreement with life sciences giant Thermo Fisher Scientific. Explaining how the relationship will work, the companies' long term vision and importantly what each party brings to this hugely significant deal.
In their Q3 2023 update, Oakley Capital Investments demonstrates resilience and growth in the face of economic challenges. With a NAV of £1,197 million and a NAV per share of 679 pence, the company made significant new investments totalling £23 million and committed €190 million to Oakley Capital Origin Fund II.
In this interview, Exec Chairman Martin Gilbert of AssetCo takes Vox Markets through how Assetco is perfectly placed to continue growing in this environment, upside potential including 30% equity interest in Parmenion and path to profitability.
In this discussion, Chris Watling (CEO Longview Economics), Patrick Armstrong (CIO Plurimi Wealth) and Edmund Shing (CIO BNP Paribas Wealth Management) take Vox Markets through the economic outlook, UK homebuilders, megacap tech, banks, commodities & industrial metals.
The impact of interest rate rises is being felt throughout the economy and proving a major headwind for UK markets. But as Singer Capital Markets’ macro specialist Jamie Constable tells Vox, receding inflationary pressures suggest a catalyst for a recovery from lowly valuations could be in sight.
In this interview, CEO Sandy Chadha of Supreme takes me through today's strong 1st half trading update and FY'24 guidance. Alongside explaining how the business is championing new best in class initiatives across the vaping industry in order to stamp-out underage use, help smokers quit and reduce the environmental footprint.
Jeremy Skillington CEO of Poolbeg Pharma (POLB) discusses their partnership with Nasdaq-Listed Biopharma company for the development of an optimised oral drug to treat a metabolic condition. Under the agreement, the Company will receive funding to work with its new partner to produce a prototype drug utilising Poolbeg's licensed oral delivery technology.
In this interview we speak to Ivan Garcia and Bren Worth, CEO and CTO of newly floated Substrate AI, about how it’s applying its cutting-edge artificial intelligence to established businesses to unlock major financial upside.